Ex Vivo Study of Laban's Role in Decreasing Hemolysis Crisis in G6PD-Deficient Patients

Table 1

Prevalence of G6PD deficiency levels and hemolysis of human blood cells treated with FBE and FBL.

G6PD deficiency categorization	Prevalence of G6PD deficiency levels	Lysis (%) of human blood cells treated with FBE	Lysis (%) of human blood cells treated with FBL
	Total samples tested 57 (100%)	—
<10% (<0.64 U/gHb)	0	—
10–30% (0.64–1.92 U/gHb)	21 (36.84%)	70.74 ± 1.26%–90.65 ± 2.09%; Mean: 82.06 ± 1.63%	19.95 ± 0.95%–26.63 ± 0.68%; Mean: 23.11 ± 0.76%
30–60% (1.92–3.84 U/gHb)	18 (31.57%)	67.13 ± 1.65%–76.09 ± 1.96%; Mean: 70.61 ± 1.36%	9.68 ± 1.35%–21.48 ± 0.96%; Mean: 14.13 ± 1.05%
>60% (>3.84 U/gHb)	18 (31.57%)	35.80 ± 2.06%–47.85 ± 1.05%; Mean: 44.06 ± 1.49%	1.21 ± 0.23%–9.71 ± 0.68%; Mean: 5.75 ± 0.64%